Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MREO |
---|---|---|
09:32 ET | 178173 | 4.18 |
09:34 ET | 108363 | 4.175 |
09:36 ET | 68624 | 4.16 |
09:38 ET | 57802 | 4.165 |
09:39 ET | 33488 | 4.155 |
09:41 ET | 60982 | 4.15 |
09:43 ET | 139666 | 4.205 |
09:45 ET | 124534 | 4.2001 |
09:48 ET | 23344 | 4.215 |
09:50 ET | 98445 | 4.2 |
09:52 ET | 31800 | 4.24 |
09:54 ET | 14770 | 4.22 |
09:56 ET | 16140 | 4.2 |
09:57 ET | 32444 | 4.215 |
09:59 ET | 120707 | 4.2 |
10:01 ET | 68803 | 4.2199 |
10:03 ET | 109781 | 4.27 |
10:06 ET | 65772 | 4.27 |
10:08 ET | 13193 | 4.255 |
10:10 ET | 44375 | 4.1861 |
10:12 ET | 47625 | 4.175 |
10:14 ET | 70419 | 4.255 |
10:15 ET | 10700 | 4.23 |
10:17 ET | 26776 | 4.215 |
10:19 ET | 17273 | 4.195 |
10:21 ET | 41381 | 4.195 |
10:24 ET | 111358 | 4.185 |
10:26 ET | 46204 | 4.16 |
10:28 ET | 53724 | 4.175 |
10:30 ET | 9334 | 4.18 |
10:32 ET | 12975 | 4.145 |
10:33 ET | 26870 | 4.155 |
10:35 ET | 28434 | 4.145 |
10:37 ET | 9521 | 4.17 |
10:39 ET | 18585 | 4.1501 |
10:42 ET | 31470 | 4.155 |
10:44 ET | 34371 | 4.142 |
10:46 ET | 25113 | 4.145 |
10:48 ET | 4212 | 4.1499 |
10:50 ET | 7068 | 4.1599 |
10:51 ET | 21272 | 4.165 |
10:53 ET | 2384 | 4.165 |
10:55 ET | 19995 | 4.135 |
10:57 ET | 41914 | 4.135 |
11:00 ET | 92326 | 4.135 |
11:02 ET | 9533 | 4.1422 |
11:04 ET | 1145 | 4.145 |
11:06 ET | 13690 | 4.1444 |
11:08 ET | 67055 | 4.15 |
11:09 ET | 31718 | 4.17 |
11:11 ET | 16476 | 4.185 |
11:13 ET | 16698 | 4.225 |
11:15 ET | 53728 | 4.235 |
11:18 ET | 58999 | 4.245 |
11:20 ET | 43485 | 4.24 |
11:22 ET | 20304 | 4.25 |
11:24 ET | 29095 | 4.25 |
11:26 ET | 4978 | 4.25 |
11:27 ET | 33597 | 4.2702 |
11:29 ET | 31070 | 4.255 |
11:31 ET | 7433 | 4.295 |
11:33 ET | 15327 | 4.295 |
11:36 ET | 69725 | 4.295 |
11:38 ET | 29128 | 4.28 |
11:40 ET | 23085 | 4.28 |
11:42 ET | 53785 | 4.28 |
11:44 ET | 3279 | 4.295 |
11:45 ET | 36080 | 4.3 |
11:47 ET | 24433 | 4.27 |
11:49 ET | 74999 | 4.24 |
11:51 ET | 3276 | 4.245 |
11:54 ET | 4739 | 4.255 |
11:56 ET | 26725 | 4.27 |
11:58 ET | 4255 | 4.27 |
12:00 ET | 1529 | 4.275 |
12:02 ET | 193175 | 4.28 |
12:03 ET | 2124 | 4.29 |
12:05 ET | 2428 | 4.2899 |
12:07 ET | 22357 | 4.37 |
12:09 ET | 38329 | 4.36 |
12:12 ET | 20438 | 4.3957 |
12:14 ET | 30510 | 4.4 |
12:16 ET | 13473 | 4.375 |
12:18 ET | 6255 | 4.3799 |
12:20 ET | 1900 | 4.38 |
12:21 ET | 3567 | 4.3699 |
12:23 ET | 10214 | 4.3499 |
12:25 ET | 2384 | 4.35 |
12:27 ET | 51981 | 4.375 |
12:30 ET | 47862 | 4.305 |
12:32 ET | 19460 | 4.29 |
12:34 ET | 64206 | 4.3 |
12:36 ET | 2783 | 4.3 |
12:38 ET | 1252 | 4.3 |
12:39 ET | 27001 | 4.29 |
12:41 ET | 13873 | 4.28 |
12:43 ET | 3291 | 4.29 |
12:45 ET | 1395 | 4.29 |
12:48 ET | 4604 | 4.3 |
12:50 ET | 27932 | 4.28 |
12:52 ET | 13513 | 4.2855 |
12:54 ET | 1800 | 4.275 |
12:56 ET | 1200 | 4.285 |
12:57 ET | 7981 | 4.29 |
12:59 ET | 3881 | 4.29 |
01:01 ET | 19824 | 4.24 |
01:03 ET | 1469 | 4.2301 |
01:06 ET | 52043 | 4.25 |
01:08 ET | 10204 | 4.25 |
01:10 ET | 3906 | 4.25 |
01:12 ET | 5732 | 4.25 |
01:14 ET | 1200 | 4.255 |
01:15 ET | 9334 | 4.2753 |
01:17 ET | 225 | 4.275 |
01:19 ET | 2111 | 4.28 |
01:21 ET | 1768 | 4.275 |
01:24 ET | 1682 | 4.275 |
01:26 ET | 4928 | 4.25 |
01:28 ET | 1364 | 4.25 |
01:30 ET | 1452 | 4.25 |
01:32 ET | 1396 | 4.25 |
01:33 ET | 1226 | 4.25 |
01:35 ET | 3326 | 4.27 |
01:37 ET | 3269 | 4.255 |
01:39 ET | 5137 | 4.255 |
01:42 ET | 8621 | 4.27 |
01:44 ET | 17374 | 4.295 |
01:46 ET | 15906 | 4.285 |
01:48 ET | 21372 | 4.255 |
01:50 ET | 9834 | 4.25 |
01:51 ET | 5376 | 4.25 |
01:53 ET | 21381 | 4.2504 |
01:55 ET | 16708 | 4.25 |
01:57 ET | 1052 | 4.255 |
02:00 ET | 173790 | 4.25 |
02:02 ET | 40344 | 4.2101 |
02:04 ET | 3212 | 4.215 |
02:06 ET | 1737 | 4.22 |
02:08 ET | 77953 | 4.215 |
02:09 ET | 202264 | 4.2 |
02:11 ET | 374 | 4.205 |
02:13 ET | 1602 | 4.21 |
02:15 ET | 15731 | 4.215 |
02:18 ET | 3934 | 4.205 |
02:20 ET | 55042 | 4.22 |
02:22 ET | 11287 | 4.2101 |
02:24 ET | 75224 | 4.245 |
02:26 ET | 4461 | 4.285 |
02:27 ET | 8121 | 4.27 |
02:29 ET | 11529 | 4.325 |
02:31 ET | 14024 | 4.35 |
02:33 ET | 10477 | 4.35 |
02:36 ET | 15076 | 4.295 |
02:38 ET | 1130 | 4.2999 |
02:40 ET | 700 | 4.295 |
02:42 ET | 4702 | 4.2801 |
02:44 ET | 4677 | 4.255 |
02:45 ET | 4670 | 4.255 |
02:47 ET | 11763 | 4.265 |
02:49 ET | 5452 | 4.2507 |
02:51 ET | 2728 | 4.26 |
02:54 ET | 4504 | 4.255 |
02:56 ET | 8762 | 4.285 |
02:58 ET | 17584 | 4.23 |
03:00 ET | 2623 | 4.24 |
03:02 ET | 2300 | 4.25 |
03:03 ET | 5035 | 4.255 |
03:05 ET | 2026 | 4.255 |
03:07 ET | 67964 | 4.275 |
03:09 ET | 3430 | 4.285 |
03:12 ET | 2354 | 4.27 |
03:14 ET | 2402 | 4.265 |
03:16 ET | 1983 | 4.265 |
03:18 ET | 4326 | 4.27 |
03:20 ET | 1000 | 4.265 |
03:21 ET | 789 | 4.27 |
03:23 ET | 9557 | 4.265 |
03:25 ET | 3979 | 4.26 |
03:27 ET | 10283 | 4.245 |
03:30 ET | 98224 | 4.265 |
03:32 ET | 11185 | 4.26 |
03:34 ET | 4200 | 4.255 |
03:36 ET | 7435 | 4.25 |
03:38 ET | 4084 | 4.255 |
03:39 ET | 19219 | 4.265 |
03:41 ET | 49142 | 4.255 |
03:43 ET | 31508 | 4.235 |
03:45 ET | 38957 | 4.255 |
03:48 ET | 44698 | 4.245 |
03:50 ET | 41729 | 4.2598 |
03:52 ET | 9640 | 4.25 |
03:54 ET | 9240 | 4.265 |
03:56 ET | 25815 | 4.235 |
03:57 ET | 83131 | 4.245 |
03:59 ET | 70911 | 4.25 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Mereo BioPharma Group PLC | 559.7M | -16.0x | --- |
Aerovate Therapeutics Inc | 708.1M | -8.1x | --- |
Olema Pharmaceuticals Inc | 696.9M | -6.1x | --- |
Hillevax Inc | 735.9M | -4.6x | --- |
ProKidney Corp | 688.1M | -4.8x | --- |
Nuvation Bio Inc | 739.0M | -9.6x | --- |
Mereo BioPharma Group plc is a biopharmaceutical company. It is focused on the development of therapeutics for rare diseases. It has developed a portfolio of clinical-stage product candidates. The Company has two rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for the treatment of severe alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD) and bronchiolitis obliterans syndrome (BOS). It also has two oncology product candidates in clinical development. It also includes Etigilimab, an antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains). Its non-core partnered programme, Navicixizumab, is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Its non-core programs available for partnership include Acumapimod and Leflutrozole. Acumapimod is a p38 MAP kinase inhibitor therapy for treatment during severe acute exacerbations of COPD (AECOPD).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $559.7M |
---|---|
Revenue (TTM) | $9.1M |
Shares Outstanding | 140.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.90 |
EPS | $-0.27 |
Book Value | $0.63 |
P/E Ratio | -16.0x |
Price/Sales (TTM) | 61.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -444.28% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.